Literature DB >> 15338189

Antiphospholipid antibodies in children with systemic lupus erythematosus: a prospective study in northern India.

Jasmina Ahluwalia1, Surjit Singh, Gurjeewan Garewal.   

Abstract

Twenty-seven children with systemic lupus erythematosus (SLE) were tested for antiphospholipid antibodies (APLA), i.e. lupus anticoagulant and immunoglobulin (Ig)G or IgM anticardiolipin antibodies (ACLA), with beta-2 glycoprotein I as cofactor, in a single-centre, prospective study over 2 years. Eighteen patients (67%) tested positively for one or the other APLA during the course of the study. Twelve children (44%) tested positively for IgG ACLA and ten (37%) for IgM ACLA, whereas eight (30%) were positive for lupus anticoagulant. In two patients with thrombosis, IgG anticardiolipin positivity was seen to be variable. Unlike the results of most other reports in the literature, lupus anticoagulant positivity was not consistently associated with thrombosis. A majority of the children (83%) tested positively for ACLA during disease activity. Immunoglobulin G and IgM ACLA positivity did not correlate significantly with disease status. The results of this prospective study would indicate that, though frequently present, APLA may be unable to be predictive of disease behaviour in children with SLE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15338189     DOI: 10.1007/s00296-004-0501-x

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  Guidelines on the investigation and management of the antiphospholipid syndrome.

Authors:  M Greaves; H Cohen; S J MacHin; I Mackie
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

2.  Factor V Leiden, antiphospholipid antibodies and thrombosis in systemic lupus erythematosus.

Authors:  R Fijnheer; D A Horbach; R C Donders; H Vilé; E von Oort; H K Nieuwenhuis; F H Gmelig-Meijling; P G de Groot; R H Derksen
Journal:  Thromb Haemost       Date:  1996-10       Impact factor: 5.249

3.  Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH.

Authors:  J T Brandt; L K Barna; D A Triplett
Journal:  Thromb Haemost       Date:  1995-12       Impact factor: 5.249

4.  Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH.

Authors:  J T Brandt; D A Triplett; B Alving; I Scharrer
Journal:  Thromb Haemost       Date:  1995-10       Impact factor: 5.249

5.  Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies.

Authors:  D A Horbach; E van Oort; R C Donders; R H Derksen; P G de Groot
Journal:  Thromb Haemost       Date:  1996-12       Impact factor: 5.249

6.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

7.  Childhood-onset systemic lupus erythematosus: antiphospholipid antibodies in 37 patients and their first-degree relatives.

Authors:  C Molta; O Meyer; C Dosquet; M Montes de Oca; M C Babron; F Danon; C Kaplan; S Clémenceau; F Castellano; M Levy
Journal:  Pediatrics       Date:  1993-12       Impact factor: 7.124

8.  Thrombosis in systemic lupus erythematosus: a French collaborative study.

Authors:  M A Montes de Oca; M C Babron; O Blétry; M Broyer; V Courtecuisse; J L Fontaine; C Loirat; J P Méry; P Reinert; B Wechsler
Journal:  Arch Dis Child       Date:  1991-06       Impact factor: 3.791

9.  Anticardiolipin antibodies in pediatric systemic lupus erythematosus.

Authors:  A Ravelli; R Caporali; G Di Fuccia; L Zonta; C Montecucco; A Martini
Journal:  Arch Pediatr Adolesc Med       Date:  1994-04

10.  Antiphospholipid antibodies in pediatric systemic lupus erythematosus.

Authors:  D E Seaman; A V Londino; C K Kwoh; T A Medsger; S Manzi
Journal:  Pediatrics       Date:  1995-12       Impact factor: 7.124

  10 in total
  5 in total

1.  Antiphospholipid antibodies in children with Kawasaki disease: a preliminary study from north India.

Authors:  M George; J Ahluwalia; A Gupta; J Masih; S K Bose; S Singh
Journal:  Rheumatol Int       Date:  2013-05-15       Impact factor: 2.631

2.  Pediatric APS: State of the Art.

Authors:  Arzu Soybilgic; Tadej Avcin
Journal:  Curr Rheumatol Rep       Date:  2020-03-03       Impact factor: 4.592

3.  Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India.

Authors:  Jasmina Ahluwalia; Surjit Singh; Shano Naseem; Deepti Suri; Amit Rawat; Anju Gupta; Joseph Masih; Sunil Bose
Journal:  Rheumatol Int       Date:  2013-04-07       Impact factor: 2.631

4.  Neuropsychiatric manifestations and antiphospholipid antibodies in pediatric onset lupus: 14 years of experience from a tertiary center of North India.

Authors:  Surjit Singh; Mukesh Kumar Gupta; Jasmina Ahluwalia; Paramjeet Singh; Prahbhjot Malhi
Journal:  Rheumatol Int       Date:  2009-03-22       Impact factor: 2.631

5.  Lupus anticoagulant in a child with celiac disease: a rare association.

Authors:  Shano Naseem; Deepti Suri; Jasmina Ahluwalia; Sadhna Bhasin Lal; B R Thapa; Surjit Singh
Journal:  Rheumatol Int       Date:  2010-11-27       Impact factor: 3.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.